Form 4: Achieve Life Sciences Director Granted 31,500 Stock Options

Achieve Life Sciences, Inc. Director Bridget A. Martell was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Summary

• Bridget A. Martell, a Director of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 31,500 stock options.
• The transaction date for this grant was June 6, 2025.
• Each option has an exercise price of $3.83.
• The options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The options have an expiration date of June 6, 2035.
• Following this transaction, Ms. Martell beneficially owns 31,500 derivative securities (stock options) and 31,500 shares of common stock underlying these options.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, and a standard practice. It doesn't indicate any negative operational or financial news, nor does it suggest extraordinary positive news beyond routine compensation.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued commitment and contribution from the director over the next year.

Negatives

• The grant of options, while common, represents potential future dilution if exercised, though this is typically factored into compensation plans.

Risks

• The value of the options is dependent on the future stock price of ACHIEVE LIFE SCIENCES, INC. exceeding the exercise price of $3.83, posing a market risk.
• If the stock price does not rise above the exercise price, the options may expire worthless.

Future Outlook

The vesting schedule of the options, tied to June 2026 or the 2026 annual meeting, indicates an expectation of continued service and performance from the director through at least that period.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Achieve Life Sciences, as a form of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of 31,500 stock options to a director with a 1-year cliff vesting schedule and a 10-year expiration is a standard compensation mechanism.
• While specific comparable companies are not mentioned, similar grants are observed across small to mid-cap biotech firms, such as those seen in compensation disclosures for directors at companies like Cassava Sciences (SAVA) or Atea Pharmaceuticals (AVIR), where equity grants form a significant part of non-executive director compensation packages, often with similar vesting periods to ensure retention and alignment.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. However, future exercise could lead to minor dilution.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will vest 100% on the earlier of June 6, 2026, or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
• The director may choose to exercise these options at any time after vesting and before the expiration date of June 6, 2035, assuming the stock price is favorable.

Key Dates

Recommendation

Keywords

ACHIEVE LIFE SCIENCES, ACHV, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Bridget Martell